Raises 2025 full year guidance to $255 – $265 million in net product revenue, cash operating expenses of $180 – $200 million, and cash flow of $30 – $40 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals Wins Court Ruling for LUMRYZ Expansion
- Avadel Pharmaceuticals announces favorable ruling in appeal of injunction
- Appeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight
- Is AVDL a Buy, Before Earnings?
- Avadel, nference announce publication of data on sodium oxybate